6Lynmn GH, Rolston KV. How we treat febrile neutropenia in patients re- ceiving cancer chemotherapy. J Oncol Pract, 2010,6 : 149-152.
7Trecarichi EM, Tumbarelto M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Esche- richia coli in patients with hematological malignancies. J Infect, 2009, 58:299-307.
8Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the U- nited States. Clin hffect Dis. 2003,36 : 1103-1110.
9Tumbarello M, Spanu T, Caira M, et al. Factors associated with mortality in bacteremie patients with hematologic malignancies. Diagn Microbiol Infect Dis ,2009,64:320-326.
10Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosoco- mial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents,2005,26:463 472.
